Please sign in to follow a disease.
Opportunistic mycosis
MONDO:0002312A mycosis that arises from infection in an immunologically compromised host.
Also known as: opportunistic systemic mycoses
149 clinical trials for this condition and its sub-types, 0 tagged with Opportunistic mycosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Opportunistic mycosis
-
Candidiasis 19 trials · 58 incl. sub-types
9 sub-types
- Cutaneous candidiasis 0 trials · 25 incl. sub-types Sub-types →
- Candidiasis, invasive 14 trials · 18 incl. sub-types Sub-types →
- Disseminated candidiasis 16 trials
- Oral candidiasis 4 trials
- Neonatal candidiasis 1 trial
- Candida glabrata infection 0 trials
- Candidal paronychia 0 trials
- Congenital candidiasis 0 trials
- Esophageal candidiasis 0 trials
-
Aspergillosis 20 trials · 56 incl. sub-types
4 sub-types
- Pulmonary aspergilloma 11 trials · 38 incl. sub-types Sub-types →
- Allergic bronchopulmonary aspergillosis 15 trials Sub-types →
- Neuroaspergillosis 1 trial
- Aspergillus niger infection 0 trials
-
Opportunistic systemic mycosis 0 trials · 23 incl. sub-types
3 sub-types
- Disseminated candidiasis 16 trials
- Penicilliosis 5 trials
- Trichosporonosis 0 trials · 2 incl. sub-types Sub-types →
-
Zygomycosis 19 trials
1 sub-type
- Basidiobolomycosis 0 trials Sub-types →
-
Pneumocystosis 19 trials
-
Cryptococcosis 5 trials · 10 incl. sub-types
1 sub-type
- Cryptococcal meningitis 7 trials
-
Fusariosis 4 trials
-
Hyalohyphomycosis 1 trial
-
Geotrichosis 0 trials
-
Maple bark strippers' lung 0 trials
-
Microsporidiosis 0 trials
1 sub-type
- Encephalitozoonosis 0 trials
-
Phaeohyphomycosis 0 trials
Most studied deeper sub-types
-
New vaccine could stop recurring yeast infections in their tracks
Vaccine OngoingThis study tests a new vaccine called Candi5V in 251 women who get frequent yeast infections (at least 3 per year). The vaccine is designed to train the body's immune system to fight Candida fungus. Researchers will check if it's safe and if it reduces future infections.
Phase 1/2 • Sponsor: LimmaTech Biologics AG • Aim: Vaccine
Last updated Jun 27, 2026 09:10 UTC
-
Can a booster for the immune system tame a Slow-Moving lung fungus?
Disease control OngoingThis trial tests whether adding interferon-gamma to standard antifungal medication can help people with chronic pulmonary aspergillosis, a progressive lung infection caused by the Aspergillus fungus. The study will include 50 adults starting antifungal treatment, who will be rand…
Phase 2 • Sponsor: Manchester University NHS Foundation Trust • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New hope for rare lung infection: weekly drug shows promise in early trial
Disease control OngoingThis study tests a drug called rezafungin for people with a long-term lung infection caused by a fungus (chronic pulmonary aspergillosis) who have few other treatment choices. About 60 adults will receive the drug once a week for 6 months. Researchers will check if the treatment …
Phase 2 • Sponsor: Mundipharma Research Limited • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a shorter steroid course be just as good for HIV-Related pneumonia?
Disease control By invitation onlyThis study compares a shortened steroid regimen (8 days for moderate, 14 days for severe pneumonia) against the standard 21-day course in 196 HIV patients with Pneumocystis pneumonia. The goal is to see if the shorter treatment is non-inferior in preventing death and complication…
Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope against deadly fungus: phase 3 trial launched
Disease control OngoingThis study tests a new drug called olorofim against a standard treatment (AmBisome followed by usual care) for a serious lung infection caused by Aspergillus fungus. About 225 adults with proven or probable infection will take part. The main goal is to see if olorofim reduces dea…
Phase 3 • Sponsor: F2G Biotech GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could women test for yeast infections at home? a swab test takes on the lab
Diagnosis OngoingResearchers are comparing the SavvyCheck Vaginal Yeast Test, a rapid swab test women use themselves, against standard vaginal yeast culture done in a lab. The study enrolls women with symptoms such as vaginal itching, discharge, soreness, or burning. The goal is to measure how ac…
Sponsor: Uniformed Services University of the Health Sciences • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
New thrush treatment shows promise in early trial
Symptom relief OngoingThis study tests a product called pHyph for treating thrush (a vaginal yeast infection) in adult women. The goal is to see if pHyph reduces symptoms like itching, burning, and irritation. 48 women will either use pHyph daily for 6 days or receive no treatment, and researchers wil…
Sponsor: Gedea Biotech AB • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can we finally outsmart recurrent yeast infections? a new study investigates
Knowledge-focused OngoingThis study aims to understand why some women get recurrent vaginal yeast infections (vulvovaginal candidiasis) and others don't. Researchers will compare the vaginal microbiome, immune markers, and metabolic profiles of women with and without the infection. By identifying key dif…
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Mystery infections in healthy people: scientists investigate
Knowledge-focused OngoingThis study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Scientists dig into the vaginal microbiome to unlock secrets of recurrent yeast infections
Knowledge-focused OngoingThis study looks at 120 Canadian women to understand why some get repeated yeast infections while others don't. Researchers will compare the vaginal yeast and bacteria of women with their first infection, those with recurrent infections, and those with yeast but no symptoms. Part…
Early phase 1 • Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Vitamin D's hidden role in TB and fungal lung disease revealed
Knowledge-focused OngoingThis study looks at whether vitamin D levels are linked to certain immune markers in people with active tuberculosis (TB), with or without a chronic fungal lung infection called aspergillosis. Researchers will compare blood samples from 300 adults—including healthy volunteers—to …
Sponsor: Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Liver patients face hidden fungal threat – new study seeks answers
Knowledge-focused OngoingThis study looks at why people with severe liver disease who are in the intensive care unit (ICU) are at risk for a dangerous fungal lung infection called invasive pulmonary aspergillosis. Researchers will study 450 patients to find better ways to predict, diagnose, and treat thi…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Candida resistance study pulled before it began
Knowledge-focused CancelledThis study was designed to learn more about different types of Candida fungus that cause serious bloodstream infections, and how they become resistant to medicines. The researchers planned to study samples from adult patients to track which species were most common and how they r…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Which drug works best for deadly fungus? researchers dig into past records
Knowledge-focused OngoingThis study looks back at medical records of 150 people treated for mucormycosis, a rare but serious fungal infection. Researchers compare two drugs—amphotericin B and isavuconazole—to see which leads to better survival and fewer side effects. The goal is to help doctors choose th…
Sponsor: Qiu Ye • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC